Replies to post #16810 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Craig seemed to hint that the problems were not related to the Glatopa 20mg/40mg production line..

We can go further than that and conclude that the compliance issue is unrelated to Glatopa, else the production/shipment of 20mg Glatopa would be affected. CW said MNTA's general counsel wouldn't let him comment in more detail, but it's very clear that Glatopa is not the cause of this problem.

CW confirmed that 20mg Glatopa and 40mg Glatopa share the same production line, as you noted.